In This Article:
-
Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin
-
Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus
-
A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory status epilepticus to be presented
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced it will present four posters that support the Company’s OV329 and OV350 pipeline programs for the treatment of conditions caused by neuronal hyperexcitability at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California.
“We are encouraged by the results of preclinical studies comparing OV329 to vigabatrin, which further elucidate OV329’s pharmacodynamic and safety profile, including its lack of accumulation in the brain, retina, and eye,” said Zhong Zhong, Ph.D., Chief Scientific Officer of Ovid Therapeutics. “These findings, alongside preclinical studies demonstrating rapid exposure in the brain, further support OV329’s potential to be a best-in-class GABA-aminotransferase (GABA-AT) inhibitor. GABA-AT inhibition is a proven mechanism of action, yet it has had limited clinical use over the years due to reported ocular toxicities associated with the first-generation medicine. OV329 may address the therapeutic needs of patients seeking anti-convulsant efficacy and improved safety without sedation.”
“Additionally, we are excited by new findings that reinforce OV350’s activity in terminating seizures and providing neuroprotective benefits in animals. OV350 is the first of multiple programs we are developing that directly activate the potassium chloride co-transporter 2 (KCC2), a fundamental target in restoring inhibitory/excitatory balance. Next year, we hope to be the first company to study a KCC2 direct activator in humans.”
POSTERS TO BE PRESENTED ON OVID DEVELOPMENT PROGRAMS:
OV329: A Potential Next-Generation GABA-AT Inhibitor
|
| Title: OV329 A Potent GABA-AT Inhibitor Does Not Accumulate in Mouse Retina: A Pharmacokinetic Study to Differentiate Eye Accumulation Between Vigabatrin |
|
|
|
|
| Title: OV329 Rapidly Inhibits GABA-AT, Elevates Brain GABA Levels and Leads to Seizure Suppression Following IV Administration in the Rat Lithium-Pilocarpine Model of Status Epilepticus |
|
|
|
|
| Title: Comparing the Effects of OV329 and Vigabatrin on GABA-AT Activity, and the Efficacy of Phasic And Tonic Inhibition |
|
|
|
OV350: A KCC2 Direct Activator
|
| Title: Evaluation of Anticonvulsant Efficacy of the KCC2 Activator, OV350, in a Rat Model of Nerve Agent Poisoning |
|
|
|
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.